CA2954897A1 - Multi-pole synchronous pulmonary artery radiofrequency ablation catheter - Google Patents
Multi-pole synchronous pulmonary artery radiofrequency ablation catheter Download PDFInfo
- Publication number
- CA2954897A1 CA2954897A1 CA2954897A CA2954897A CA2954897A1 CA 2954897 A1 CA2954897 A1 CA 2954897A1 CA 2954897 A CA2954897 A CA 2954897A CA 2954897 A CA2954897 A CA 2954897A CA 2954897 A1 CA2954897 A1 CA 2954897A1
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- annular ring
- ablation
- catheter
- power
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001147 pulmonary artery Anatomy 0.000 title claims abstract description 222
- 238000007674 radiofrequency ablation Methods 0.000 title claims abstract description 29
- 230000005405 multipole Effects 0.000 title claims abstract description 28
- 230000001360 synchronised effect Effects 0.000 title claims abstract description 28
- 238000002679 ablation Methods 0.000 claims abstract description 236
- 238000000034 method Methods 0.000 claims abstract description 127
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 27
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000002638 denervation Effects 0.000 claims abstract description 19
- 230000002889 sympathetic effect Effects 0.000 claims description 38
- 210000004126 nerve fiber Anatomy 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 12
- 238000004891 communication Methods 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 abstract description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 9
- 239000011780 sodium chloride Substances 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 5
- 210000004026 tunica intima Anatomy 0.000 abstract description 5
- 230000010412 perfusion Effects 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 44
- 229940079593 drug Drugs 0.000 description 31
- 239000003814 drug Substances 0.000 description 31
- 238000010586 diagram Methods 0.000 description 23
- 210000005036 nerve Anatomy 0.000 description 23
- 238000005259 measurement Methods 0.000 description 21
- 230000006872 improvement Effects 0.000 description 12
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000036593 pulmonary vascular resistance Effects 0.000 description 11
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000000004 hemodynamic effect Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000010935 stainless steel Substances 0.000 description 9
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 8
- 210000003050 axon Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000002474 noradrenergic effect Effects 0.000 description 8
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 7
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 7
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 7
- 230000004872 arterial blood pressure Effects 0.000 description 7
- 230000001746 atrial effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000030214 innervation Effects 0.000 description 7
- 230000003730 sympathetic denervation Effects 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 210000003484 anatomy Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 229910001000 nickel titanium Inorganic materials 0.000 description 6
- 241000282465 Canis Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000004642 Polyimide Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000003205 diastolic effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002592 echocardiography Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001721 polyimide Polymers 0.000 description 5
- 239000002861 polymer material Substances 0.000 description 5
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 238000003848 UV Light-Curing Methods 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000004007 neuromodulation Effects 0.000 description 4
- 230000006425 pulmonary artery denervation Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
- 229960005080 warfarin Drugs 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 229910001020 Au alloy Inorganic materials 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229910000990 Ni alloy Inorganic materials 0.000 description 3
- 208000005228 Pericardial Effusion Diseases 0.000 description 3
- 229910000566 Platinum-iridium alloy Inorganic materials 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 3
- 229960005156 digoxin Drugs 0.000 description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 210000004912 pericardial fluid Anatomy 0.000 description 3
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical class [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 108010065372 Dynorphins Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 101800001904 NT-proBNP Proteins 0.000 description 2
- 102400001263 NT-proBNP Human genes 0.000 description 2
- 239000004962 Polyamide-imide Substances 0.000 description 2
- 102100024622 Proenkephalin-B Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 2
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 108091008698 baroreceptors Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 2
- 229960003065 bosentan Drugs 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920002312 polyamide-imide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 210000001774 pressoreceptor Anatomy 0.000 description 2
- 201000010298 pulmonary valve insufficiency Diseases 0.000 description 2
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 2
- 210000003492 pulmonary vein Anatomy 0.000 description 2
- 208000030390 pulmonic stenosis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 238000011298 ablation treatment Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000008867 communication pathway Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000000393 hypersympathetic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004686 stellate ganglion Anatomy 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/1206—Generators therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00029—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids open
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00541—Lung or bronchi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/1206—Generators therefor
- A61B2018/1226—Generators therefor powered by a battery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1407—Loop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1467—Probes or electrodes therefor using more than two electrodes on a single probe
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plasma & Fusion (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Otolaryngology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Surgical Instruments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3201993A CA3201993A1 (en) | 2014-07-11 | 2015-07-10 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462023781P | 2014-07-11 | 2014-07-11 | |
| US62/023,781 | 2014-07-11 | ||
| US14/666,214 US9827036B2 (en) | 2012-11-13 | 2015-03-23 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| US14/666,214 | 2015-03-23 | ||
| US14/672,013 | 2015-03-27 | ||
| US14/672,010 | 2015-03-27 | ||
| US14/672,021 US9872720B2 (en) | 2012-11-13 | 2015-03-27 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| US14/672,010 US9820800B2 (en) | 2012-11-13 | 2015-03-27 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| US14/672,021 | 2015-03-27 | ||
| US14/672,013 US9918776B2 (en) | 2012-11-13 | 2015-03-27 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| PCT/US2015/039930 WO2016007851A1 (en) | 2014-07-11 | 2015-07-10 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3201993A Division CA3201993A1 (en) | 2014-07-11 | 2015-07-10 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2954897A1 true CA2954897A1 (en) | 2016-01-14 |
Family
ID=55064957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2954897A Pending CA2954897A1 (en) | 2014-07-11 | 2015-07-10 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| CA3201993A Pending CA3201993A1 (en) | 2014-07-11 | 2015-07-10 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3201993A Pending CA3201993A1 (en) | 2014-07-11 | 2015-07-10 | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP4647111A2 (enExample) |
| JP (4) | JP6608924B2 (enExample) |
| KR (4) | KR102766112B1 (enExample) |
| CN (2) | CN112704559B (enExample) |
| AU (4) | AU2015287691B2 (enExample) |
| BR (1) | BR112017000610B1 (enExample) |
| CA (2) | CA2954897A1 (enExample) |
| RU (1) | RU2692219C2 (enExample) |
| SG (2) | SG11201700223PA (enExample) |
| WO (1) | WO2016007851A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018173052A1 (en) | 2017-03-20 | 2018-09-27 | Sonievie Ltd. | Pulmonary hypertension treatment |
| US11730506B2 (en) | 2010-10-18 | 2023-08-22 | Sonivie Ltd. | Ultrasound transducer and uses thereof |
| US12201444B2 (en) | 2012-05-31 | 2025-01-21 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201402610QA (en) | 2011-12-09 | 2014-10-30 | Metavention Inc | Therapeutic neuromodulation of the hepatic system |
| US20150111918A1 (en) | 2012-03-08 | 2015-04-23 | Medtronic Ardian Luxembourg S.a.r.l | Immune system neuromodulation and associated systems and methods |
| US11241267B2 (en) | 2012-11-13 | 2022-02-08 | Pulnovo Medical (Wuxi) Co., Ltd | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| CN102908191A (zh) | 2012-11-13 | 2013-02-06 | 陈绍良 | 多极同步肺动脉射频消融导管 |
| US9827036B2 (en) | 2012-11-13 | 2017-11-28 | Pulnovo Medical (Wuxi) Co., Ltd. | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| US12082868B2 (en) | 2012-11-13 | 2024-09-10 | Pulnovo Medical (Wuxi) Co., Ltd. | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
| US20190069949A1 (en) | 2014-12-03 | 2019-03-07 | Metavention, Inc. | Systems and methods for modulatng nerves or other tissue |
| EP3209235B1 (en) | 2015-01-28 | 2019-06-26 | St. Jude Medical, Cardiology Division, Inc. | Thermal mapping catheter |
| US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
| RU2694583C1 (ru) * | 2016-12-13 | 2019-07-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) | Способ лечения резистивной артериальной легочной гипертензии |
| CN111491582B (zh) | 2017-11-28 | 2023-12-05 | 圣犹达医疗用品心脏病学部门有限公司 | 受控式可膨胀导管 |
| EP3768185B1 (en) | 2018-05-21 | 2023-06-14 | St. Jude Medical, Cardiology Division, Inc. | Radio-frequency ablation and direct current electroporation catheters |
| CN113692248B (zh) | 2018-12-13 | 2024-10-25 | Nxt生物医疗有限责任公司 | 血氧治疗方法和装置 |
| CN110897710B (zh) * | 2019-11-30 | 2021-08-31 | 杭州堃博生物科技有限公司 | 肺部神经消融系统的控制方法、系统以及计算机介质 |
| US20220047326A1 (en) * | 2020-08-13 | 2022-02-17 | Biosense Webster (Israel) Ltd. | Applying Bipolar Ablation Energy Between Shorted Electrode Groups |
| EP4167886B1 (en) | 2020-08-18 | 2024-05-01 | St. Jude Medical, Cardiology Division, Inc. | High-density electrode catheters with magnetic position tracking |
| US12082877B2 (en) | 2021-01-22 | 2024-09-10 | CRC EP, Inc. | Ablation catheter and operation method of same |
| MX2023011506A (es) | 2021-04-07 | 2023-12-07 | Btl Medical Dev A S | Dispositivo y metodo de ablacion de campo pulsado. |
| EP4108197A1 (en) | 2021-06-24 | 2022-12-28 | Gradient Denervation Technologies | Systems for treating tissue |
| HUE072155T2 (hu) | 2021-07-06 | 2025-10-28 | Btl Medical Dev A S | Impulzusos elektromos teret alkalmazó ablációs eszköz |
| EP4598461A1 (en) | 2022-10-05 | 2025-08-13 | BTL Medical Development A.S. | Pulsed field ablation device and method |
| WO2025227077A1 (en) * | 2024-04-25 | 2025-10-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Radiofrequency ablation device |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0861676B1 (en) * | 1993-11-10 | 2003-10-01 | Medtronic Cardiorhythm | Electrode array catheter |
| US5797905A (en) * | 1994-08-08 | 1998-08-25 | E. P. Technologies Inc. | Flexible tissue ablation elements for making long lesions |
| US6575969B1 (en) * | 1995-05-04 | 2003-06-10 | Sherwood Services Ag | Cool-tip radiofrequency thermosurgery electrode system for tumor ablation |
| US5755760A (en) * | 1996-03-11 | 1998-05-26 | Medtronic, Inc. | Deflectable catheter |
| US20050010095A1 (en) * | 1999-04-05 | 2005-01-13 | Medtronic, Inc. | Multi-purpose catheter apparatus and method of use |
| WO2001037723A2 (en) * | 1999-11-22 | 2001-05-31 | Boston Scientific Limited | Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
| JP3895531B2 (ja) * | 2000-09-01 | 2007-03-22 | オリンパス株式会社 | 電気手術装置 |
| US6866662B2 (en) * | 2002-07-23 | 2005-03-15 | Biosense Webster, Inc. | Ablation catheter having stabilizing array |
| WO2004039273A2 (en) * | 2002-10-31 | 2004-05-13 | C.R. Bard, Inc. | Electrophysiology catheter with biased tip |
| US7235070B2 (en) * | 2003-07-02 | 2007-06-26 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Ablation fluid manifold for ablation catheter |
| US8657814B2 (en) * | 2005-08-22 | 2014-02-25 | Medtronic Ablation Frontiers Llc | User interface for tissue ablation system |
| JP2009543607A (ja) * | 2006-07-10 | 2009-12-10 | ボエッジ メディカル， インコーポレイテッド | 心房細動の治療のための方法および装置 |
| JP4027411B1 (ja) * | 2007-03-29 | 2007-12-26 | 日本ライフライン株式会社 | 電極カテーテル |
| US8712550B2 (en) * | 2008-12-30 | 2014-04-29 | Biosense Webster, Inc. | Catheter with multiple electrode assemblies for use at or near tubular regions of the heart |
| US8540662B2 (en) * | 2009-03-24 | 2013-09-24 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Medical devices having an atraumatic distal tip segment |
| CA2780608C (en) * | 2009-11-11 | 2019-02-26 | Innovative Pulmonary Solutions, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
| US9907607B2 (en) * | 2009-12-30 | 2018-03-06 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Guide and flexible sleeve for use with catheters |
| US8369923B2 (en) * | 2010-04-14 | 2013-02-05 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Dual-deflecting electrophysiology catheter |
| US9943363B2 (en) | 2010-04-28 | 2018-04-17 | Biosense Webster, Inc. | Irrigated ablation catheter with improved fluid flow |
| EP3100696B1 (en) * | 2010-10-25 | 2023-01-11 | Medtronic Ardian Luxembourg S.à.r.l. | Catheter apparatuses having multi-electrode arrays for renal neuromodulation |
| US8792962B2 (en) * | 2010-12-30 | 2014-07-29 | Biosense Webster, Inc. | Catheter with single axial sensors |
| CN102949176B (zh) * | 2011-08-26 | 2014-11-12 | 苏州信迈医疗器械有限公司 | 肾神经消融术中肾神经分布标测方法及用于该方法的导管 |
| EP2775899B1 (en) * | 2011-11-07 | 2017-08-23 | Medtronic Ardian Luxembourg S.à.r.l. | Endovascular nerve monitoring devices and associated systems |
| US9005100B2 (en) * | 2011-12-15 | 2015-04-14 | The Board Of Trustees Of The Leland Stanford Jr. University | Apparatus and methods for treating pulmonary hypertension |
| CN102908191A (zh) * | 2012-11-13 | 2013-02-06 | 陈绍良 | 多极同步肺动脉射频消融导管 |
| CN202982207U (zh) * | 2012-11-13 | 2013-06-12 | 陈绍良 | 治疗肺动脉高压的多极同步射频消融导管 |
| CN103908334A (zh) * | 2012-12-31 | 2014-07-09 | 上海微创电生理医疗科技有限公司 | 多电极消融导管 |
| US9050010B2 (en) * | 2012-12-31 | 2015-06-09 | Biosense Webster (Israel) Ltd. | Double loop lasso with single puller wire for bi-directional actuation |
-
2015
- 2015-07-10 CN CN202010799806.7A patent/CN112704559B/zh active Active
- 2015-07-10 RU RU2017101338A patent/RU2692219C2/ru active
- 2015-07-10 KR KR1020247009010A patent/KR102766112B1/ko active Active
- 2015-07-10 KR KR1020177003851A patent/KR102219632B1/ko active Active
- 2015-07-10 JP JP2017522463A patent/JP6608924B2/ja active Active
- 2015-07-10 SG SG11201700223PA patent/SG11201700223PA/en unknown
- 2015-07-10 EP EP25187226.3A patent/EP4647111A2/en active Pending
- 2015-07-10 KR KR1020237009116A patent/KR102650430B1/ko active Active
- 2015-07-10 CA CA2954897A patent/CA2954897A1/en active Pending
- 2015-07-10 BR BR112017000610-3A patent/BR112017000610B1/pt active IP Right Grant
- 2015-07-10 SG SG10201800251YA patent/SG10201800251YA/en unknown
- 2015-07-10 WO PCT/US2015/039930 patent/WO2016007851A1/en not_active Ceased
- 2015-07-10 CN CN201580049382.XA patent/CN107072707B/zh active Active
- 2015-07-10 CA CA3201993A patent/CA3201993A1/en active Pending
- 2015-07-10 AU AU2015287691A patent/AU2015287691B2/en active Active
- 2015-07-10 KR KR1020217003781A patent/KR102513522B1/ko active Active
- 2015-07-10 EP EP15818364.0A patent/EP3166524B1/en active Active
- 2015-07-10 EP EP22155626.9A patent/EP4014908B1/en active Active
-
2019
- 2019-07-04 AU AU2019204804A patent/AU2019204804B2/en active Active
- 2019-10-24 JP JP2019193400A patent/JP2020044338A/ja active Pending
-
2020
- 2020-10-07 AU AU2020250197A patent/AU2020250197B2/en active Active
-
2021
- 2021-11-29 JP JP2021192988A patent/JP7653346B2/ja active Active
-
2022
- 2022-04-26 AU AU2022202710A patent/AU2022202710B2/en active Active
-
2024
- 2024-12-02 JP JP2024209230A patent/JP2025027101A/ja active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11730506B2 (en) | 2010-10-18 | 2023-08-22 | Sonivie Ltd. | Ultrasound transducer and uses thereof |
| US12364501B2 (en) | 2010-10-18 | 2025-07-22 | Sonivie Ltd. | Ultrasound transducer and uses thereof |
| US12201444B2 (en) | 2012-05-31 | 2025-01-21 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
| WO2018173052A1 (en) | 2017-03-20 | 2018-09-27 | Sonievie Ltd. | Pulmonary hypertension treatment |
| EP3600434A4 (en) * | 2017-03-20 | 2021-01-06 | Sonievie Ltd. | Pulmonary hypertension treatment |
| US11318331B2 (en) | 2017-03-20 | 2022-05-03 | Sonivie Ltd. | Pulmonary hypertension treatment |
| US12251582B2 (en) | 2017-03-20 | 2025-03-18 | Sonivie Ltd. | Pulmonary hypertension treatment |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202710B2 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| US12458427B2 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| US20160338774A1 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| US11241267B2 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| US20250186099A1 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| HK40051288A (zh) | 多极同步肺动脉射频消融导管 | |
| HK40051288B (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| HK1234978A1 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| HK1234978B (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| HK1235654A1 (en) | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter | |
| HK1235654B (zh) | 多极同步肺动脉射频消融导管 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |
|
| EEER | Examination request |
Effective date: 20180731 |